REFERENCES
  1. Black RE, Morris SS, Bryce J. Where and why are 10 million children dying every year? Lancet . 2003;361:2226-2234.
  2. Duke T. Neonatal pneumonia in developing countries. Arch Dis Child Fetal Neonatal Ed . 2005;90:F211-F219.
  3. Mortality GBD and Causes of Death C. Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980-2015: a systematic analysis for the Global Burden of Disease Study 2015. Lancet . 2016;388:1459-1544.
  4. Chakraborty M, McGreal EP, Kotecha S. Acute lung injury in preterm newborn infants: mechanisms and management. Paediatr Respir Rev . 2010;11:162-170.
  5. Heidemann SM, Nair A, Bulut Y, Sapru A. Pathophysiology and Management of Acute Respiratory Distress Syndrome in Children. Pediatr Clin North Am . 2017;64:1017-1037.
  6. Sugitharini V, Pavani K, Prema A, Berla Thangam E. TLR-mediated inflammatory response to neonatal pathogens and co-infection in neonatal immune cells. Cytokine . 2014;69:211-217.
  7. Martin R. Pathophysiology, clinical manifestations, and diagnosis of respiratory distress syndrome in the newborn. In: UpToDate, Garcia-Prats, JA (Ed), UpToDate, Waltham, MA, USA, 2020.
  8. Sardesai S, Biniwale M, Wertheimer F, Garingo A, Ramanathan R. Evolution of surfactant therapy for respiratory distress syndrome: past, present, and future. Pediatr Res . 2017;81:240-248.
  9. Pediatric Acute Lung Injury Consensus Conference G. Pediatric acute respiratory distress syndrome: consensus recommendations from the Pediatric Acute Lung Injury Consensus Conference. Pediatr Crit Care Med . 2015;16:428-439.
  10. Yehya N, Servaes S, Thomas NJ, Nadkarni VM, Srinivasan V. Corticosteroid exposure in pediatric acute respiratory distress syndrome. Intensive Care Med . 2015;41:1658-1666.
  11. Doyle LW, Cheong JL, Ehrenkranz RA, Halliday HL. Early (< 8 days) systemic postnatal corticosteroids for prevention of bronchopulmonary dysplasia in preterm infants. Cochrane Database Syst Rev . 2017;10:CD001146.
  12. Monteverde-Fernandez N, Cristiani F, McArthur J, Gonzalez-Dambrauskas S. Steroids in pediatric acute respiratory distress syndrome.Ann Transl Med . 2019;7:508.
  13. Mokra D, Mokry J, Drgova A, Petraskova M, Bulikova J, Calkovska A. Intratracheally administered corticosteroids improve lung function in meconium-instilled rabbits. J Physiol Pharmacol . 2007;58 Suppl 5:389-398.
  14. Lin CH, Jeng MJ, Yang YC, Hsiao YH, Kou YR. Comparison of different dosing strategies of intratracheally instilled budesonide on meconium injured piglet lungs. Pediatr Pulmonol . 2017;52:891-899.
  15. Bassler D, Plavka R, Shinwell ES, Hallman M, Jarreau PH, Carnielli V, Van den Anker JN, Meisner C, Engel C, Schwab M, Halliday HL, Poets CF, Group NT. Early inhaled budesonide for the prevention of bronchopulmonary dysplasia. N Engl J Med . 2015;373:1497-1506.
  16. Tukova J, Smisek J, Zlatohlavkova B, Plavka R, Markova D. Early inhaled budesonide in extremely preterm infants decreases long-term respiratory morbidity. Pediatr Pulmonol . 2020;55:1124-1130.
  17. Bassler D, Shinwell ES, Hallman M, Jarreau PH, Plavka R, Carnielli V, Meisner C, Engel C, Koch A, Kreutzer K, van den Anker JN, Schwab M, Halliday HL, Poets CF; Neonatal European Study of Inhaled Steroids Trial Group. Long-term effects of inhaled budesonide for bronchopulmonary dysplasia. N Engl J Med . 2018;378:148-157.
  18. Shah SS, Ohlsson A, Halliday HL, Shah VS. Inhaled versus systemic corticosteroids for preventing bronchopulmonary dysplasia in ventilated very low birth weight preterm neonates. Cochrane Database Syst Rev . 2017;10:CD002058.
  19. Chakraborty M, Kotecha S. Pulmonary surfactant in newborn infants and children. Breathe . 2013;9:476-488.
  20. Boel L, Banerjee S, Chakraborty M. Postnatal steroids in extreme preterm infants: Intra-tracheal instillation using surfactant as a vehicle. Paediatr Respir Rev . 2018;25:78-84.
  21. Chen CM, Chang CH, Chao CH, Wang MH, Yeh TF. Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration. Drug Deliv . 2019;26:604-611.
  22. Nimmo AJ, Carstairs JR, Patole SK, Whitehall J, Davidson K, Vink R. Intratracheal administration of glucocorticoids using surfactant as a vehicle. Clin Exp Pharmacol Physiol . 2002;29:661-665.
  23. Ricci F, Catozzi C, Ravanetti F, Murgia X, D’Alo F, Macchidani N, Sgarbi E, Di Lallo V, Saccani F, Pertile M, Cacchioli A, Catinella S, Villetti G, Civelli M, Amadei F, Stellari FF, Pioselli B, Salomone F. In vitro and in vivo characterization of poractant alfa supplemented with budesonide for safe and effective intratracheal administration.Pediatr Res . 2017;82:1056-1063.
  24. Huang LT, Yeh TF, Kuo YL, Chen PC, Chen CM. Effect of surfactant and budesonide on the pulmonary distribution of fluorescent dye in mice.Pediatr Neonatol . 2015;56:19-24.
  25. Yang CF, Jeng MJ, Soong WJ, Lee YS, Tsao PC, Tang RB. Acute pathophysiological effects of intratracheal instillation of budesonide and exogenous surfactant in a neonatal surfactant-depleted piglet model. Pediatr Neonatol . 2010;51:219-226.
  26. Lin CH, Jeng MJ, Kuo BI, Kou YR. Effects of surfactant lavage combined with intratracheal budesonide instillation on meconium-injured piglet lungs. Pediatr Crit Care Med . 2016;17:e287-95.
  27. Gie AG, Regin Y, Salaets T, Casiraghi C, Salomone F, Deprest J, Vanoirbeek J, Toelen J. Intratracheal budesonide/surfactant attenuates hyperoxia-induced lung injury in preterm rabbits. Am J Physiol Lung Cell Mol Physiol . 2020;319:L949-L956.
  28. Hillman NH, Kothe TB, Schmidt AF, Kemp MW, Royse E, Fee E, Salomone F, Clarke MW, Musk GC, Jobe AH. Surfactant plus budesonide decreases lung and systemic responses to injurious ventilation in preterm sheep.Am J Physiol Lung Cell Mol Physiol . 2020;318:L41-L48.
  29. Ikegami M, Berry D, elKady T, Pettenazzo A, Seidner S, Jobe A. Corticosteroids and surfactant change lung function and protein leaks in the lungs of ventilated premature rabbits. J Clin Invest . 1987;79:1371-1378.
  30. Venkataraman R, Kamaluddeen M, Hasan SU, Robertson HL, Lodha A. Intratracheal administration of budesonide-surfactant in prevention of bronchopulmonary dysplasia in very low birth weight infants: a systematic review and meta-analysis. Pediatr Pulmonol . 2017;52:968-975.
  31. Zhong YY, Li JC, Liu YL, Zhao XB, Male M, Song DK, Bai Y. Early intratracheal administration of corticosteroid and pulmonary surfactant for preventing bronchopulmonary dysplasia in preterm infants with neonatal respiratory distress syndrome: a meta-analysis.Curr Med Sci . 2019;39:493-499.
  32. McEvoy CT, Ballard PL, Ward RM, Rower JE, Wadhawan R, Hudak ML, Weitkamp JH, Harris J, Asselin J, Chapin C, Ballard RA. Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE). Pediatr Res . 2020;88:629-636.
  33. Yeh TF, Lin HC, Chang CH, Wu TS, Su BH, Li TC, Pyati S, Tsai CH. Early intratracheal instillation of budesonide using surfactant as a vehicle to prevent chronic lung disease in preterm infants: a pilot study.Pediatrics . 2008;121:e1310-1318.
  34. Deliloglu B, Tuzun F, Cengiz MM, Ozkan H, Duman N. Endotracheal surfactant combined with budesonide for neonatal ARDS. Front Pediatr . 2020;8:210.
  35. Kothe TB, Sadiq FH, Burleyson N, Williams HL, Anderson C, Hillman NH. Surfactant and budesonide for respiratory distress syndrome: an observational study. Pediatr Res . 2020;87:940-945.
  36. Haegens A, Heeringa P, van Suylen RJ, Steele C, Aratani Y, O’Donoghue RJ, Mutsaers SE, Mossman BT, Wouters EF, Vernooy JH. Myeloperoxidase deficiency attenuates lipopolysaccharide-induced acute lung inflammation and subsequent cytokine and chemokine production. J Immunol. 2009;182:7990-7996.
  37. Knapp S, Florquin S, Golenbock DT, van der Poll T. Pulmonary lipopolysaccharide (LPS)-binding protein inhibits the LPS-induced lung inflammation in vivo. J Immunol . 2006;176:3189-3195.